Vaccine offers some protection during malaria season

“In this study, we administered 491 inoculations in a rural setting without a problem, and the dosages were delivered in a matter of seconds. It shows that this approach is feasible from both a logistical and public health standpoint.”

According to the investigators, a malaria vaccine employed in mass vaccination programs to eliminate P falciparum from geographically defined areas would need to prevent malaria infection or transmission in at least 80% of recipients throughout the malaria transmission season.

Clinical trials now underway in Africa, Europe, and the US have been designed to boost the PfSPZ Vaccine’s efficacy by increasing dosage levels and varying the timing and number of doses.

The experimental vaccine is also being examined in demographic groups other than healthy adults, including adolescents, children, and infants.